raloxifene hydrochloride has been researched along with Diabetes Mellitus, Type 2 in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abu-Zaid, A; Alkhwildi, JA; Almuqayyid, F; de Souza, IGO; Hejji, AT; Hoilat, GJ; Martins, CEC; Santos, HO; Shi, H; Varkaneh, HK | 1 |
| Azizian, H; Bashiri, H; Ebrahimi, MN; Khaksari, M; Raji-Amirhasani, A | 1 |
| Azizian, H; Ebrahimi, MN; Karam, GA; Khaksari, M; Raji-Amirhasani, A; Sepehri, G | 1 |
| Isaka, Y; Sato, M; Sugihara, T; Ye, W | 1 |
| Lovre, D; Mauvais-Jarvis, F; Xu, B | 1 |
| Domeki, N; Ikeda, S; Kasai, K; Kawagoe, Y; Matsumura, M; Monden, T; Nakatani, Y; Shimizu, H; Yanagi, K | 1 |
| Nakamura, T; Sakai, A | 1 |
| Inokuchi, N; Kishikawa, H; Mori, H; Okada, Y; Sugimoto, H; Tanaka, Y | 1 |
| Reincke, M | 1 |
| Anderson, PW; Barrett-Connor, E; Ensrud, KE; Harper, K; Krueger, KA; Mason, TM; Sashegyi, A | 1 |
| Araki, S; Chin, M; Guo, B; Haneda, M; Isono, M; Isshiki, K; Kashiwagi, A; Koya, D; Sato, H; Sugimoto, T | 1 |
| Asano, A; Kobayashi, J; Mabuchi, H; Muramoto, H; Murase, Y; Yamaaki, N; Yonezawa, K | 1 |
| Simorre, B | 1 |
| Chabin, M; Gautier, JF; Gourdy, P; Guerci, B; Hadjadj, S; Mauco, G; Ragot, S; Roudaut, N; Zaoui, P | 1 |
| Anderson, PW; Andersson, B; Bengtsson, BA; Holm, G; Johannsson, G; Mason, T; Pavo, I; Sashegyi, A | 1 |
3 review(s) available for raloxifene hydrochloride and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The Effect of Raloxifene Treatment on Lipid Profile in Elderly Individuals: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Topics: Aged; Diabetes Mellitus, Type 2; Humans; Lipids; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Triglycerides | 2021 |
The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights.
Topics: Aging; Animals; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Humans; Indoles; Insulin Resistance; Models, Biological; Obesity; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2017 |
[Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases].
Topics: Adiponectin; beta Catenin; Diabetes Mellitus, Type 2; Female; Fractures, Spontaneous; Humans; Hyperlipidemias; Hypertension; Life Style; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Signal Transduction; Spinal Fractures; Wnt Proteins | 2010 |
4 trial(s) available for raloxifene hydrochloride and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Blood Glucose; Bone and Bones; Bone Density Conservation Agents; Cholesterol, LDL; Collagen Type I; Diabetes Mellitus, Type 2; Female; Homocysteine; Humans; Male; Middle Aged; Peptides; Postmenopause; Raloxifene Hydrochloride | 2013 |
Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Statistics as Topic; Time Factors; Treatment Outcome | 2003 |
Effect of raloxifene -- a selective oestrogen receptor modulator -- on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Middle Aged; Pilot Projects; Placebos; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome | 2007 |
Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.
Topics: Aged; Androgens; Blood Coagulation Factors; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Estrogen Antagonists; Female; Glucose Clamp Technique; Humans; Hyperandrogenism; Insulin Resistance; Insulin-Like Growth Factor I; Lipoproteins; Middle Aged; Postmenopause; Raloxifene Hydrochloride | 2002 |
8 other study(ies) available for raloxifene hydrochloride and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Protective effects of combining SERMs with estrogen on metabolic parameters in postmenopausal diabetic cardiovascular dysfunction: The role of cytokines and angiotensin II.
Topics: Angiotensin II; Animals; Cytokines; Diabetes Mellitus, Type 2; Estrogens; Female; Interleukin-10; Postmenopause; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Necrosis Factor-alpha | 2022 |
The effects of alone and combination tamoxifen, raloxifene and estrogen on lipid profile and atherogenic index of ovariectomized type 2 diabetic rats.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Estrogens; Female; Lipids; Menopause; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Streptozocin; Tamoxifen | 2020 |
Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Comorbidity; Diabetes Mellitus, Type 2; Female; Health Care Costs; Humans; Incidence; Japan; Middle Aged; Osteoporosis; Osteoporotic Fractures; Patient Acceptance of Health Care; Prevalence; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2016 |
Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment.
Topics: Aged; Bone Density Conservation Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Menopause; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride | 2010 |
[Diabetes, Conn syndrome and osteoporosis. What is new in diagnosis and therapy?].
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Hyperaldosteronism; Hyperglycemia; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2003 |
Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Estradiol; Female; Fibronectins; Glomerular Mesangium; Kidney; Mice; Mice, Mutant Strains; Ovariectomy; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators | 2005 |
Effects of raloxifene on adipocytokines in Japanese osteoporotic postmenopausal women with and without type 2 diabetes.
Topics: Adipose Tissue; Aged; Aged, 80 and over; Biomarkers; Body Fat Distribution; Bone Density Conservation Agents; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Inflammation; Japan; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride | 2006 |
[41th Congress of EASD (European Association for The Study of Diabetes) 10 to 15 September 2005, Athens, Greece].
Topics: Aged; Albuminuria; Antihypertensive Agents; Bone Density Conservation Agents; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Pioglitazone; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Spironolactone; Thiazolidinediones; Time Factors | 2006 |